Cigna vs Elevance Health
CI and ELV side by side, both in accident and health insurance and medical. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CI and ELV compare
Elevance Health is the larger company, worth 1.2 times as much as Cigna ($91.1B against $78.8B).
Cigna grew revenue faster over the last twelve months (7.8% versus 6.3% for Elevance Health).
Both pay dividends: Cigna yields 2.1% and Elevance Health 1.6%.
Elevance Health scores higher on the StockData Score (15 against 8 for Cigna), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CI | ELV |
|---|---|---|
| Size and price | ||
| Market cap | $78.8B | $91.1B |
| Share price | $298.23 | $420.07 |
| Change, 1 year | −0.30% | 24.9% |
| Change, 5 years | 39.3% | −0.47% |
| Beta (5Y) | 0.33 | 0.44 |
| Employees | 68K | 97K |
| StockData Score | ||
| Total score | 8 | 15 (better) |
| Valuation score | 2 | 4 (better) |
| Growth score | 2 | 2 |
| Performance score | 0 | 3 (better) |
| Health score | 2 | 2 |
| Dividend score | 2 | 4 (better) |
| Valuation | ||
| P/E | – | 18.7× |
| P/S | 0.3× (better) | 0.5× |
| P/B | 1.8× (better) | 2.0× |
| EV/EBITDA | 8.2× (better) | 12.4× |
| P/FCF | – | 14.5× |
| PEG | – | 14.81 |
| FCF yield | – | 6.9% |
| Fair value | – | $477.08 |
| Margin of safety | – | 11.9% |
| Growth | ||
| Revenue growth (TTM) | 7.8% (better) | 6.3% |
| Revenue growth, 5Y average | 11.4% (better) | 10.3% |
| Net income growth (TTM) | – | −7.4% |
| EPS growth (TTM) | – | −4.3% |
| EPS growth, 5Y average | −0.69% | 7.0% (better) |
| Profitability | ||
| Gross margin | 20.6% | 89.1% (better) |
| Operating margin | 3.5% (better) | 2.7% |
| Net margin | – | 2.5% |
| FCF margin | – | 3.1% |
| Return on equity | – | 11.2% |
| Return on invested capital | 12.1% (better) | 11.5% |
| Financial health | ||
| Debt / equity | 0.75 | 0.69 (better) |
| Net debt / EBITDA | 1.94 (better) | −0.70 |
| Interest coverage | 7.2× (better) | 3.8× |
| Current ratio | 0.85 | 1.52 (better) |
| Altman Z-score | 2.80 | 3.03 (better) |
| Piotroski F-score | 7 (better) | 6 |
| Dividends and buybacks | ||
| Dividend yield | 2.1% (better) | 1.6% |
| Payout ratio | – | 30.3% |
| Years of dividend growth | 5 | – |
| Dividend growth, 5Y average | 173% | – |
| Buyback yield | 1.3% | 3.0% (better) |
| Shareholder yield | 3.4% | 4.6% (better) |
| Ownership | ||
| Held by institutions | 89.9% | 94.0% |
| Held by insiders | 0.41% | 0.19% |
| Insider net buying, 12 months | −$65.8M | $493K (better) |
| Superinvestors holding | 4 | 8 (better) |
| Short interest, % of float | 2.6% | 2.2% |
Go deeper
- CI stock overview
- CI income statement
- CI valuation and score
- ELV stock overview
- ELV income statement
- ELV valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.